Good morning :)
Place Order
Add to Watchlist

Alivus Life Sciences Ltd

ALIVUS Share Price

1,046.001.95% (+20.00)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹12,581 cr, stock is ranked 477

Stock is 3.35x as volatile as Nifty

How to use scorecard? Learn more

With a market cap of ₹12,581 cr, stock is ranked 477

Stock is 3.35x as volatile as Nifty

ALIVUS Performance & Key Metrics

ALIVUS Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
25.915.390.49%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
36.276.670.83%

ALIVUS Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 
100%
Analysts have suggested that investors can buy this stock

from 4 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

ALIVUS Company Profile

Alivus Life Sciences Ltd develops and manufactures active pharmaceutical ingredients (APIs) and provides contract development and manufacturing services for chronic therapeutic areas.

Investor Presentation

View older View older 

May 15, 2025

PDF
View Older Presentations

ALIVUS Similar Stocks (Peers)

Compare with peers Compare with peers 

ALIVUS Similar Stocks (Peers)

Compare with peers Compare with peers 
PE Ratio
37.12
37.12
1Y Return
12.73%
12.73%
Buy Reco %
87.88
87.88
PE Ratio
23.31
23.31
1Y Return
0.56%
0.56%
Buy Reco %
74.19
74.19
PE Ratio
19.88
19.88
1Y Return
11.86%
11.86%
Buy Reco %
56.67
56.67
PE Ratio
56.78
56.78
1Y Return
12.44%
12.44%
Buy Reco %
72.00
72.00
PE Ratio
21.76
21.76
1Y Return
9.78%
9.78%
Buy Reco %
48.28
48.28
Compare with Peers

ALIVUS Sentiment Analysis

ALIVUS Sentiment Analysis

New
Crisp summary & key insights to decode earnings calls instantly

ALIVUS Stock Summary · May 2025

Alivus Life Sciences demonstrated strong financial performance in Q4 FY'25, achieving a revenue of Rs. 650 crores, a 21.1% year-on-year increase, driven by robust growth across various segments. Despite this success, the company faces challenges such as a rising cash conversion cycle and market erosion of approximately 4% to 4.5%, which could impact future revenue growth. Management remains optimistic about mid-teen volume growth for FY'26, supported by significant capital expenditures of Rs. 550 to Rs. 600 crores aimed at expanding production capacity and enhancing R&D capabilities. While pricing pressures and regulatory concerns pose risks, the company’s net debt-free status and strong cash flow position it well for continued investment and innovation in a dynamic market landscape.

ALIVUS Stock Growth Drivers
ALIVUS Stock Growth Drivers
5
  • Strong Financial Performance

    Alivus Life Sciences reported robust financial results for Q4 and FY'25, with revenues reaching Rs.

  • Expansion and Capital Investment

    The company has made significant capital investments, reporting a capital expenditure (CAPEX) of Rs. 166

ALIVUS Stock Challenges
ALIVUS Stock Challenges
4
  • Margin Compression

    The company is experiencing a decrease in normalized margins, which are expected to range between

  • CDMO Segment Performance Challenges

    The CDMO segment is facing a soft performance characterized by a price erosion of 4%

ALIVUS Forecast

ALIVUS Forecasts

Price

Revenue

Earnings

ALIVUS

ALIVUS

Income

Balance Sheet

Cash Flow

ALIVUS Income Statement

ALIVUS Income Statement

Industry refers to the sub-sector this company belongs to.
Higher than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 20.95%, vs industry avg of 9.02%

Increasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.4% to 0.6%

Higher than Industry Net Income
Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 19.21%, vs industry avg of 15.29%

Loading...

Financial YearFY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Total Revenue0.25886.861,549.301,885.982,137.912,190.182,295.252,421.452,421.45
Raw Materialssubtract0.04633.56668.66948.17977.961,068.561,025.211,704.301,704.30
Power & Fuel Costsubtract0.0057.8176.7574.19100.92115.60112.46
Employee Costsubtract0.15106.28142.28149.13168.72180.18258.16
Selling & Administrative Expensessubtract0.0044.2042.0548.5048.6465.4764.12
Operating & Other expensessubtract0.08-203.15135.6174.11210.9189.11149.02
Depreciation/Amortizationsubtract0.0019.2629.3733.3937.8842.0953.4560.6160.61
Interest & Other Itemssubtract0.000.6133.5287.5527.960.551.552.412.41
Taxes & Other Itemssubtract0.4232.71107.97119.37146.20161.65160.40168.50168.52
EPS-8.0036.1029.0432.6136.3638.1138.4339.6339.63
DPS0.000.000.000.0021.0042.0022.505.000.00
Payout ratio0.000.000.000.000.581.100.590.130.00

ALIVUS Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2025FY 2025

Annual Report Pending

Investor Presentation

May 15PDF
Jan 23PDF
Oct 24PDF
FY 2024FY 2024

Annual report

PDF

Investor Presentation

Jul 21PDF
FY 2023FY 2023

Annual report

PDF

Investor Presentation

Apr 27PDF
Jan 27PDF
Nov 17PDF
+3 more
FY 2022FY 2022

Annual report

PDF
 

ALIVUS Stock Peers

ALIVUS Past Performance & Peer Comparison

ALIVUS Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Alivus Life Sciences Ltd25.915.390.49%
Sun Pharmaceutical Industries Ltd37.126.040.95%
Cipla Ltd23.314.591.05%
Dr Reddy's Laboratories Ltd19.883.980.59%

ALIVUS Stock Price Comparison

Compare ALIVUS with any stock or ETF
Compare ALIVUS with any stock or ETF
ALIVUS
Loading...

ALIVUS Holdings

ALIVUS Shareholdings

ALIVUS Promoter Holdings Trend

ALIVUS Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

ALIVUS Institutional Holdings Trend

ALIVUS Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

ALIVUS Shareholding Pattern

ALIVUS Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding74.99%3.59%1.59%6.57%13.25%

Jun 2024

Sep 2024

Dec 2024

Mar 2025

ALIVUS Shareholding History

ALIVUS Shareholding History

Dec '23MarJunSepDec '24Mar4.57%5.01%4.82%7.85%6.74%6.57%

Mutual Funds Invested in ALIVUS

Mutual Funds Invested in ALIVUS

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Alivus Life Sciences Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
1.0517%0.46%0.26%30/112 (+10)
0.9170%1.58%0.03%51/60 (-33)
0.5291%0.62%-0.05%52/64 (-6)

Compare 3-month MF holding change on Screener

ALIVUS Insider Trades & Bulk Stock Deals

ALIVUS Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing ALIVUS stock

smallcases containing ALIVUS stock

Looks like this stock is not in any smallcase yet.

ALIVUS Events

ALIVUS Events

ALIVUS Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

ALIVUS Dividend Trend

No dividend trend available

ALIVUS Upcoming Dividends

ALIVUS Upcoming Dividends

No upcoming dividends are available

ALIVUS Past Dividends

ALIVUS Past Dividends

Cash Dividend

Ex DateEx DateOct 17, 2023

Interim
Interim | Div/Share: ₹22.50

Dividend/Share

22.50

Ex DateEx Date

Oct 17, 2023

Cash Dividend

Ex DateEx DateMar 24, 2023

Interim
Interim | Div/Share: ₹21.00

Dividend/Share

21.00

Ex DateEx Date

Mar 24, 2023

Cash Dividend

Ex DateEx DateSep 15, 2022

Final
Final | Div/Share: ₹10.50

Dividend/Share

10.50

Ex DateEx Date

Sep 15, 2022

Cash Dividend

Ex DateEx DateNov 22, 2021

Interim
Interim | Div/Share: ₹10.50

Dividend/Share

10.50

Ex DateEx Date

Nov 22, 2021

ALIVUS Stock News & Opinions

ALIVUS Stock News & Opinions

Corporate
Board of Alivus Life Sciences recommends final dividend

Alivus Life Sciences announced that the Board of Directors of the Company at its meeting held on 15 May 2025, inter alia, have recommended the final dividend of Rs 5 per equity Share (i.e. 250%) , subject to the approval of the shareholders.Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Earnings
Alivus Life Sciences standalone net profit rises 44.85% in the March 2025 quarter

Net profit of Alivus Life Sciences rose 44.85% to Rs 141.87 crore in the quarter ended March 2025 as against Rs 97.94 crore during the previous quarter ended March 2024. Sales rose 21.05% to Rs 649.55 crore in the quarter ended March 2025 as against Rs 536.60 crore during the previous quarter ended March 2024. For the full year,net profit rose 3.13% to Rs 485.63 crore in the year ended March 2025 as against Rs 470.89 crore during the previous year ended March 2024. Sales rose 4.54% to Rs 2386.88 crore in the year ended March 2025 as against Rs 2283.21 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales649.55536.60 21 2386.882283.21 5 OPM %30.5526.36 -28.6029.53 - PBDT207.27144.21 44 714.74684.74 4 PBT191.30129.68 48 654.13631.29 4 NP141.8797.94 45 485.63470.89 3 Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Corporate
Alivus Life Sciences to hold board meeting

Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 15 May 2025.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Alivus Life Sciences allots 92,096 equity shares under ESOS

Alivus Life Sciences has allotted 92,096 equity shares under ESOS on 30 April 2025. Consequent to the allotment, the paid up equity share capital has increased to 12,26,29,148 equity shares of Rs. 2 each aggregating to Rs. 24,52,58,296/-. Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Alivus Life Sciences standalone net profit rises 15.32% in the December 2024 quarter

Net profit of Alivus Life Sciences rose 15.32% to Rs 136.96 crore in the quarter ended December 2024 as against Rs 118.77 crore during the previous quarter ended December 2023. Sales rose 12.05% to Rs 641.84 crore in the quarter ended December 2024 as against Rs 572.80 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales641.84572.80 12 OPM %29.6530.13 - PBDT200.31173.87 15 PBT185.15160.69 15 NP136.96118.77 15 Powered by Capital Market - Live

4 months agoCapital Market - Live
Spotlight
Alivus Life jumps after Q3 PAT climbs 15% YoY to Rs 137 cr

Profit before tax (PBT) climbed 15.22% YoY to Rs 185.14 crore in Q3 FY25. For Q3FY25, EBITDA was at Rs 200.8 crore, a growth of 15.2% YoY. EBITDA margin stood at 31.3%, up 90 bps YoY. On segmental front, the revenue from Generic API grew by 16.9% YoY to Rs 596.6 crore in Q3 FY25 while revenue from CDMO declined 14.29% YoY to Rs 30 crore in Q3 FY25. Yasir Rawjee, MD & CEO, Alivus Life Sciences, said, 'The start of the new year marks a notable shift for us as we transition to Alivus Life Sciences. I am pleased to report that our Q3 performance reflects this renewed energy, with growth across both GPL and Non-GPL segments. Geographically, regions like India, Europe, ROW and Japan contributed to the growth. Alivus Life Sciences (Formerly Glenmark Life Sciences) is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes. It has a diversified portfolio of 161 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan, and the Rest of the World (RoW).Powered by Capital Market - Live

4 months agoCapital Market - Live
Spotlight
Alivus Life Sciences Ltd leads gainers in 'A' group

Avantel Ltd, Sunteck Realty Ltd, Spandana Sphoorty Financial Ltd and Jai Corp Ltd are among the other gainers in the BSE's 'A' group today, 21 January 2025.Alivus Life Sciences Ltd surged 6.82% to Rs 1178.4 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 11436 shares were traded on the counter so far as against the average daily volumes of 5071 shares in the past one month. Avantel Ltd spiked 6.10% to Rs 143.6. The stock was the second biggest gainer in 'A' group. On the BSE, 3.06 lakh shares were traded on the counter so far as against the average daily volumes of 1.35 lakh shares in the past one month. Sunteck Realty Ltd soared 5.43% to Rs 517.7. The stock was the third biggest gainer in 'A' group. On the BSE, 1.38 lakh shares were traded on the counter so far as against the average daily volumes of 12899 shares in the past one month. Spandana Sphoorty Financial Ltd advanced 4.99% to Rs 366.95. The stock was the fourth biggest gainer in 'A' group. On the BSE, 2.38 lakh shares were traded on the counter so far as against the average daily volumes of 1.94 lakh shares in the past one month. Jai Corp Ltd gained 4.22% to Rs 157. The stock was the fifth biggest gainer in 'A' group. On the BSE, 71599 shares were traded on the counter so far as against the average daily volumes of 2.64 lakh shares in the past one month. Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Glenmark Life Sciences renamed as Alivus Life Sciences

Glenmark Life Sciences announced its change of identity to Alivus Life Sciences, marking an exciting new chapter in its journey. This is consequent to the acquisition by Nirma, a diversified conglomerate with interest in consumer products, chemicals, and pharmaceuticals. The change is reflective of the company's evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space. The new identity, Alivus Life Sciences, represents vitality and growth with a renewed focus. It embodies the optimism and transformation the company is embracing as it enters the next phase of its journey. The official website is now alivus.com. Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Glenmark Life Sciences declare Quarterly Result

Glenmark Life Sciences will hold a meeting of the Board of Directors of the Company on 23 January 2025.Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Glenmark Life Sciences renamed Alivus Life Sciences

Glenmark Life Sciences has been renamed Alivus Life Sciences with effect from 17 December 2024. Powered by Capital Market - Live

5 months agoCapital Market - Live

Frequently asked questions

Frequently asked questions

  1. What is the share price of Alivus Life Sciences Ltd (ALIVUS) today?

    The share price of ALIVUS as on 12th June 2025 is ₹1046. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Alivus Life Sciences Ltd (ALIVUS) share?

    The past returns of Alivus Life Sciences Ltd (ALIVUS) share are
    • Past 1 week: -4.52%
    • Past 1 month: -11.25%
    • Past 3 months: 4.19%
    • Past 6 months: -2.27%
    • Past 1 year: 18.36%
    • Past 3 years: 119.86%
    • Past 5 years: 37.07%

  3. What are the peers or stocks similar to Alivus Life Sciences Ltd (ALIVUS)?
  4. What is the dividend yield % of Alivus Life Sciences Ltd (ALIVUS) share?

    The current dividend yield of Alivus Life Sciences Ltd (ALIVUS) is 0.49.

  5. What is the market cap of Alivus Life Sciences Ltd (ALIVUS) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Alivus Life Sciences Ltd (ALIVUS) is ₹12581.75 Cr as of 12th June 2025.

  6. What is the 52 week high and low of Alivus Life Sciences Ltd (ALIVUS) share?

    The 52-week high of Alivus Life Sciences Ltd (ALIVUS) is ₹1335.10 and the 52-week low is ₹819.05.

  7. What is the PE and PB ratio of Alivus Life Sciences Ltd (ALIVUS) stock?

    The P/E (price-to-earnings) ratio of Alivus Life Sciences Ltd (ALIVUS) is 25.91. The P/B (price-to-book) ratio is 5.39.

  8. Which sector does Alivus Life Sciences Ltd (ALIVUS) belong to?

    Alivus Life Sciences Ltd (ALIVUS) belongs to the Health Care sector & Pharmaceuticals sub-sector.

  9. How to buy Alivus Life Sciences Ltd (ALIVUS) shares?

    You can directly buy Alivus Life Sciences Ltd (ALIVUS) shares on Tickertape. Simply sign up, connect your demat account and place your order.